Centre de Recherche du CHU de Québec, Université Laval, Axe Neurosciences, T2-07, 2705, Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC, G1K 0A6, Canada.
J Neurol. 2024 Jun;271(6):3682-3689. doi: 10.1007/s00415-024-12337-w. Epub 2024 Apr 12.
Our limited understanding of complex neurodegenerative disorders has held us back on the development of efficient therapies. While several approaches are currently being considered, it is still unclear what will be most successful. Among the latest and more novel ideas, the concept of blood or plasma transfusion from young healthy donors to diseased patients is gaining momentum and attracting attention beyond the scientific arena. While young or healthy blood is enriched with protective and restorative components, blood from older subjects may accumulate neurotoxic agents or be impoverished of beneficial factors. In this commentary, we present an overview of the compelling evidence collected in various animal models of brain diseases (e.g., Alzheimer, Parkinson, Huntington) to the actual clinical trials that have been conducted to test the validity of blood-related treatments in neurodegenerative diseases and argue in favor of such approach.
我们对复杂神经退行性疾病的有限了解阻碍了我们开发有效的治疗方法。虽然目前正在考虑几种方法,但尚不清楚哪种方法最成功。在最新和更新颖的想法中,从年轻健康供体向患病患者输注血液或血浆的概念正在获得动力,并引起科学界以外的关注。虽然年轻或健康的血液富含保护性和修复性成分,但来自老年受试者的血液可能会积聚神经毒性物质或缺乏有益因素。在这篇评论中,我们概述了在各种脑疾病(例如阿尔茨海默病、帕金森病、亨廷顿病)的动物模型中收集的令人信服的证据,以及已经进行的实际临床试验,以测试血液相关治疗方法在神经退行性疾病中的有效性,并支持这种方法。